2-(氨基甲基)-1,3-噻唑-4-甲腈 | 302341-70-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(氨基甲基)-1,3-噻唑-4-甲腈
• 中文别名: 2-(氨基甲基)噻唑-4-甲腈
• 英文名称: 2-(aminomethyl)-thiazole-4-carbonitrile
• 英文别名: 4-cyano-2-aminomethylthiazole；2-aminomethyl-4-cyano-thiazol；2-(Aminomethyl)thiazole-4-carbonitrile；2-(aminomethyl)-1,3-thiazole-4-carbonitrile
• CAS: 302341-70-4
• 化学式: C₅H₅N₃S
• mdl: MFCD13179604
• 分子量: 139.181
• InChiKey: TVPJJKGFBGKYGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  90.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  2-(氨基甲基)-1,3-噻唑-4-甲腈 在 N-甲基吗啉 、 盐酸羟胺 作用下， 以 甲醇 为溶剂， 反应 15.0h， 生成
  参考文献：
  名称：

  Non-covalent thrombin inhibitors featuring p 3 -heterocycles with P 1 -monocyclic arginine surrogates

  摘要：

  Investigations on P-2-P-3-heterocyclic dipeptide surrogates directed towards identification of an orally bioavailable thrombin inhibitor led us to pursue novel classes of achiral, non-covalent P-1-arginine derivatives. The design. synthesis. and biological activity of inhibitors NC1-NC30 that feature three classes of monocyclic P-1-arginine surrogates will be disclosed: (1) (hetero)aromatic amidines, amines and hydrox amidines, (2) 2-aminopyrazines. and (3) 2-aminopyrimidines and 2-aminotetrahydropyrimidines. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00129-4
• 作为产物：
  描述：

  tert-butyl ((4-cyanothiazol-2-yl)methyl)carbamate 在 碘代三甲硅烷 、 甲醇 作用下， 以 乙腈 为溶剂， 反应 0.67h， 以99%的产率得到2-(氨基甲基)-1,3-噻唑-4-甲腈
  参考文献：
  名称：

  Synthesis and Biological Characterization of the Histone Deacetylase Inhibitor Largazole and C7- Modified Analogues

  摘要：

  Largazole 4a and analogues with modifications at the C7 position, as well as 2,4'-bithiazole 5a, have been synthesized using an acyclic cross-metathesis of the corresponding depsipeptide structures assembled by N-C6(O) or C15(O)-N lactam formation. Similar to the parent system 4a, the series of largazole depsipeptides 4b-d, but not 2,4'-bithiazole 5a, showed a marked inhibition of recombinant HDAC1 and selectivity over HDAC4, as well as strong pro-apoptotic effects on the NB4 leukemia cell line, but they failed to induce differentiation to mature granulocytes. Functional assays of the analogues correlated with the in vitro activities, as shown by increased H3 and a-tubulin acetylation levels and p21(WAF1/C1P1) up-regulation in NB4 cells. The activity of the natural product HDACi largazole 4a is not significantly altered by the presence of groups of different size (H, Et, Ph) at C7 on the dihydrothiazole ring.

  DOI：

  10.1021/jm100244y

文献信息

• [EN] MATRIPTASE INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE MATRIPTASE ET PROCEDES D'UTILISATION ASSOCIES
  申请人：DENDREON CORP

  公开号：WO2004058688A1

  公开（公告）日：2004-07-15

  The present invention provides matriptase inhibitors and compositions thereof useful for treating cancer. Martripase is a trypsin-like serine protease active in the development of cancerous conditions, such as tumors and metastasis of cancer.

  本发明提供了适用于治疗癌症的matriptase抑制剂及其组合物。Matriptase是一种类似于胰蛋白酶的丝氨酸蛋白酶，在癌症病变的发展中起着活跃作用，如肿瘤和癌症的转移。
• Low-molecular serine proteases inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals
  申请人：——

  公开号：US20040048815A1

  公开（公告）日：2004-03-11

  The invention relates to novel amidines and quanidines, the production and use thereof and the use thereof as trypsine-type serine protease competitive inhibitors, especially thrombine and compliment proteases CIs and C1r. The invention also relates to pharmaceutical compositions which contain said compounds as active ingredients, in addition to the use of the compounds as thrombine inhibitors, anticoagulants, compliment inhibitors and anti-inflammatory agents. The novel compositions are characterised by the linkage of a serine protease inhibitor having amidine or quanidine functions with an alkyl radical having two or more hydroxyl functions, whereby said alkyl radical is derived from sugar derivates.Several sugar structural components or components derived from sugar can therefore be linked to each other. Said principle of linking sugar derivates enables oral active compounds to be obtained.

  本发明涉及新型的氨基脲和胍类化合物，其生产和使用以及作为胰蛋白酶类丝氨酸蛋白酶竞争性抑制剂的用途，特别是作为凝血酶和补体蛋白酶CIs和C1r的抑制剂。本发明还涉及含有所述化合物作为活性成分的制药组合物，以及将该化合物用作凝血酶抑制剂、抗凝剂、补体抑制剂和抗炎剂的用途。新型组合物的特点是将具有氨基脲或胍类功能的丝氨酸蛋白酶抑制剂与具有两个或更多羟基功能的烷基基团连接起来，所述烷基基团源自糖衍生物。因此，几种糖结构组分或从糖中衍生的组分可以相互连接。这种将糖衍生物连接起来的原理使得可以获得口服活性化合物。
• Matriptase inhibitors and methods of use
  申请人：Dendreon Corporation

  公开号：US20040186060A1

  公开（公告）日：2004-09-23

  The present invention provides matriptase inhibitors and compositions thereof useful for treating cancer. Martripase is a trypsin-like serine protease active in the development of cancerous conditions, such as tumors and metastasis of cancer.

  本发明提供了阻断Matriptase的药物以及其组合物，可用于治疗癌症。Matriptase是一种类似胰蛋白酶的丝氨酸蛋白酶，在癌症的发展过程中起着作用，如肿瘤和癌症的转移。
• ISOXAZOLO-PYRIDINE DERIVATIVES
  申请人：Buettelmann Bernd

  公开号：US20120184538A1

  公开（公告）日：2012-07-19

  The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R 1 to R 6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.

  本发明涉及式I的异噁唑-吡啶衍生物，其中X，R1至R6如此处所述。该化合物在GABA A α5受体结合位点上具有活性，并且可用于治疗认知障碍，如阿尔茨海默病。
• Isoxazolo-pyridine derivatives
  申请人：Roche Palo Alto LLC

  公开号：US08877782B2

  公开（公告）日：2014-11-04

  The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.

  本发明涉及式I的异噁唑-吡啶衍生物，其中X，R1至R6如本文所述。该化合物对GABA A α5受体结合位点具有活性，可用于治疗认知障碍，如阿尔茨海默病。